{"id":9132,"date":"2012-04-19T10:55:54","date_gmt":"2012-04-19T14:55:54","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=9132"},"modified":"2012-04-19T10:55:54","modified_gmt":"2012-04-19T14:55:54","slug":"biotech-company-secures-38-million-series-d-funds","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=9132","title":{"rendered":"Biotech Company Secures $38 Million Series D Funds"},"content":{"rendered":"<p><a href=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/08\/CurrencyDice_M4DGROUP_Flickr.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-full wp-image-5768\" title=\"Currency Dice\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/08\/CurrencyDice_M4DGROUP_Flickr.jpg\" alt=\"Currency dice (MD4 Group\/Flickr)\" width=\"300\" height=\"200\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/08\/CurrencyDice_M4DGROUP_Flickr.jpg 300w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/08\/CurrencyDice_M4DGROUP_Flickr-150x100.jpg 150w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><a href=\"http:\/\/www.alderbio.com\/assets\/File\/20120419_Alder_Series_D_Final.pdf\">Alder BioPharmaceuticals Inc.<\/a> in Bothell, Washington says\u00a0it closed $38 million in financing today to support clinical studies of its two lead compounds. The series D round, the fourth financing installment after initial start-up, is led by <a href=\"http:\/\/www.novo.dk\/composite-67.htm\">Novo Ventures<\/a>, the venture capital subsidiary of Danish pharmaceutical maker Novo Nordisk.<\/p>\n<p>Alder BioPharmaceuticals has developed an <a href=\"http:\/\/www.alderbio.com\/25\/ANTIBODY%20PRODUCTION\/\">antibody production technology<\/a> it calls Mab Xpress based on a yeast expression system that the company says has the ability to make fully functional whole antibodies at a fraction of the time and cost of other technologies. The process, says the company, can generate full-length, function-modifying antibodies at high expression levels much faster than traditional mammalian systems.<\/p>\n<p>Proceeds from the round are expected to support Alder&#8217;s two lead compounds. ALD518 is a monoclonal antibody now in <a href=\"http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01403064\">phase 2 clinical trials<\/a> on cancer-related disorders. ALD518 is in development with Bristol-Myers Squibb as well as a treatment for autoimmune diseases.<\/p>\n<p>ALD403 is Alder&#8217;s calcitonin gene-related peptide inhibiting antibody for treatment of migraine. A clinical trial of ALD403 in healthy volunteers is planned to begin later this month.<\/p>\n<p>Novo Ventures, a new investor in Alder BioPharmaceuticals, was joined in the round by existing investors Sevin Rosen Funds, Ventures West, WRF Capital, H.I.G. Ventures, Delphi Ventures, and TPG Biotech. Peter Bisgaard, a partner with Novo Ventures, will join Alder&#8217;s board of directors.<\/p>\n<p>Read more: <a href=\"http:\/\/sciencebusiness.technewslit.com\/?p=2743\">Bristol-Myers Squibb, Biotech Partner on Alzheimer\u2019s Test<\/a><\/p>\n<p>Hat tip: <a href=\"http:\/\/finance.fortune.cnn.com\/category\/term-sheet\/\">Term Sheet\/Fortune<\/a><\/p>\n<p>Image: <a href=\"http:\/\/www.flickr.com\/photos\/m4dgroup\/6001102681\/in\/photostream\/\">MD4 Group\/Flickr<\/a><\/p>\n<p style=\"text-align: center;\">*\u00a0\u00a0\u00a0\u00a0 *\u00a0\u00a0\u00a0\u00a0 *<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alder BioPharmaceuticals Inc. in Bothell, Washington says\u00a0it closed $38 million in financing today to support clinical studies of its two lead compounds. The series D round, the fourth financing installment after initial start-up, is led by Novo Ventures, the venture capital subsidiary of Danish pharmaceutical maker Novo Nordisk. Alder BioPharmaceuticals has developed an antibody production [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[31,21,51,28,23,24,64,27,19],"class_list":["post-9132","post","type-post","status-publish","format-standard","hentry","category-finance","tag-biomedical","tag-biotech","tag-cancer","tag-clinical-trials","tag-equity","tag-investment","tag-life-sciences","tag-pharmaceuticals","tag-venture-capital"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/9132","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9132"}],"version-history":[{"count":3,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/9132\/revisions"}],"predecessor-version":[{"id":9135,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/9132\/revisions\/9135"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9132"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9132"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9132"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}